Liminal Biosciences Inc (LMNL) NPV
Liminal BioSciences Inc. is a Canada-based clinical-stage biotechnology company. The Company is focused on discovery and development of small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases. Its lead small molecule product candidate, fezagepras (PBI-4050) has completed the clinical phase of the Phase I multi-ascending dose, (MAD), clinical trial and the Company is in the process of evaluating the pharmacokinetic (PK) data set from the phase I MAD clinical trial. The Company is also developing a selective GPR84 antagonist candidate and an oral, selective OXER1 antagonist candidate. The GPR84 and OXER1 antagonist programs are in the preclinical stage. GPR84 is an inflammatory target primarily expressed on cells associated with the immune system and its expression levels increase during periods of inflammatory stress. OXER1 is a G protein-coupled receptor (GPCR) that is highly selective for 5-Oxo-eicosatetraenoic acid (5-oxo-ETE).
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.